NeoGenomics, Inc. (NEO) News
Filter NEO News Items
NEO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NEO News Highlights
- For NEO, its 30 day story count is now at 3.
- Over the past 23 days, the trend for NEO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about NEO are FL.
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record DecemberThe S&P 500 came within inches of a record high Thursday, but had to settle for a minute gain as the stock market faded and small caps broke a trend of outperformance. The S&P 500 climbed less than 0.1%. The Nasdaq composite closed fractionally lower after erasing modest gains. |
NeoGenomics to Appeal RulingFORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary ... |
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy ResponseFT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual ... |
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare ConferenceFT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New ... |
Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call TranscriptNeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call — Third Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note this call is being recorded, and an audio replay will be […] |
Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key MetricsAlthough the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
NeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023Net loss decreases by 50% and Adjusted EBITDA increases by 129% Year-over-Year |
NeoGenomics Reports Third Quarter 2023 ResultsThird Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ... |
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseAkoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |